Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Tempest Therapeutics, Inc. (TPST)
USD1.07
+0.09 (+9.13%)
US NASDAQ Healthcare Biotechnology
Address
7000 Shoreline Court 94080
Brisbane, CA, US
Brisbane, CA, US
CEO
Matthew Angel
Website
tempesttx.com
IPO
2012-11-12
CIK 1544227 ISIN US87978U2078
Description
Tempest Therapeutics Inc. is an oncology company, currently in the clinical development phase, dedicated to advancing novel small molecule drugs designed to combat cancer. The firm's pipeline highlights two key therapeutic candidates: TPST-1495, a compound functioning as a dual inhibitor of EP2 and EP4 receptors (which are implicated in prostaglandin E2 signaling), currently undergoing initial human trials for solid tumor indications. The second candidate, TPST-1120, is a targeted blocker of peroxisome proliferator-activated receptor alpha, also progressing through Phase 1 studies for solid tumors. Beyond these clinical assets, Tempest is exploring TREX-1, a pivotal cellular enzyme known for its role in regulating the innate immune response within cancerous growths. Established in 2011, Tempest Therapeutics Inc. is headquartered in South San Francisco, California, having previously operated as a subsidiary of Inception Sciences, Inc.
Market Cap & Enterprise Value
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD1.07
+0.09 (+9.13%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
196.4K
Beta
-1.78
Float Shares
4.16M
Free Float %
93.7%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +13.59% | +4.50% | -7.11% | -11.44% | -76.96% | -27.18% | -68.09% | -92.63% | -98.91% | -99.99% | -99.99% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
1.07
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-47.94
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-322.0% Q1'26: +19.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-366.9% Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-85.1% ★ Q1'26: +218.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.32× Q1'26: -0.07× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2021 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
277.0K
est: 399.3K (-30.6%)
|
653.0K
est: 658.8K (-0.9%)
|
295.0K
est: 398.0K (-25.9%)
|
—
est: 137.8K (-100.0%)
|
—
|
—
|
17.85M
17.85M – 17.85M
|
57.82M
57.82M – 57.82M
+223.8% YoY
|
4.30M
4.30M – 4.30M
-92.6% YoY
|
117.70M
117.70M – 117.70M
+2,637.2% YoY
|
| EBITDA |
-71.86M
est: -71.62M (-0.3%)
|
-79.82M
|
-84.27M
|
-26.65M
est: -70.44M (+62.2%)
|
-40.14M
|
-25.79M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-73.14M
est: -71.73M (-2.0%)
|
-82.06M
|
-84.30M
|
-27.02M
est: -70.95M (+61.9%)
|
-40.53M
|
-26.06M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-73.22M
est: -72.95M (-0.4%)
|
-82.26M
est: -204.03B (+100.0%)
|
-84.58M
est: -119.65B (+99.9%)
|
-28.30M
est: -73.09M (+61.3%)
|
-41.84M
est: -481.12M (+91.3%)
|
-26.26M
est: -25.31M (-3.7%)
|
-5.56M
-5.56M – -5.56M
+78.0% YoY
|
-5.02M
-5.02M – -5.02M
+9.7% YoY
|
-3.69M
-3.69M – -3.69M
+26.4% YoY
|
-17.55M
-17.55M – -17.55M
-375.3% YoY
|
| SGA |
51.59M
|
49.22M
|
5.93M
|
9.82M
|
13.55M
|
13.97M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-608.25
est: -596.27 (-2.0%)
|
-575.73
est: -7,312.50 (+92.1%)
|
-72,406.33
est: -4,288.13 (-1,588.5%)
|
-7.80
est: -83.37 (+90.6%)
|
-1.50
est: -17.49 (+91.4%)
|
-6.33
est: -6.10 (-3.8%)
|
-1.34
-1.34 – -1.34
+78.0% YoY
|
-1.21
-1.21 – -1.21
+9.7% YoY
|
-0.89
-0.89 – -0.89
+26.4% YoY
|
-4.23
-4.23 – -4.23
-375.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-27.36M
OE per share TTM
-1.80
Owner's Yield
-339.81%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
12,575.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
2.26M
Insider transactions (90d)
0
Beneficial owners (>5%)
30
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Versant Vantage II GP, L.P. | 2.12M | 20.50% | — | 2.12M | — | 2.12M | PN | — | 2022-05-09 | ↗ |
| 2 | Versant Vantage II, L.P. | 2.12M | 20.50% | 2.12M | — | 2.12M | — | PN | — | 2022-05-09 | ↗ |
| 3 | 15 GP, LLC | 1.77M | 9.30% | — | 1.77M | — | 1.77M | OO | Delaware Limited Liability Company | 2021-04-13 | ↗ |
| 4 | Anthony A. Florence, Jr. | 1.77M | 9.30% | — | 1.77M | — | 1.77M | IN | States citizen | 2021-04-13 | ↗ |
| 5 | Baskett | 1.77M | 9.30% | — | 1.77M | — | 1.77M | IN | States citizen | 2021-04-13 | ↗ |
| 6 | Mohamad H. Makhzoumi | 1.77M | 9.30% | — | 1.77M | — | 1.77M | IN | States citizen | 2021-04-13 | ↗ |
| 7 | NEA Partners 15, L.P. | 1.77M | 9.30% | — | 1.77M | — | 1.77M | PN | Delaware Limited Partnership | 2021-04-13 | ↗ |
| 8 | New Enterprise Associates 15, L.P. | 1.77M | 9.30% | — | 1.77M | — | 1.77M | PN | Delaware Limited Partnership | 2021-04-13 | ↗ |
| 9 | Peter W. Sonsini | 1.77M | 9.30% | — | 1.77M | — | 1.77M | IN | States citizen | 2021-04-13 | ↗ |
| 10 | Scott D. Sandell | 1.77M | 9.30% | — | 1.77M | — | 1.77M | IN | States citizen | 2021-04-13 | ↗ |
| 11 | Versant Ventures IV, LLC | 1.18M | 11.40% | 1.18M | — | 1.18M | — | OO | — | 2022-05-09 | ↗ |
| 12 | Versant Venture Capital IV, L.P. | 1.17M | 11.30% | 1.17M | — | 1.17M | — | PN | — | 2022-05-09 | ↗ |
| 13 | Ikarian Healthcare Fund GP, L.P. | 1.08M | 5.70% | — | 1.08M | — | 1.08M | PN | Delaware | 2021-04-07 | ↗ |
| 14 | EcoR1 Capital, LLC | 1.05M | 11.00% | — | 1.05M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 15 | Oleg Nodelman | 1.05M | 11.00% | — | 1.05M | — | — | HC, IN | Delaware | 2023-02-14 | ↗ |
| 16 | Versant Ventures VI GP-GP, LLC | 997.9K | 14.40% | — | 997.9K | — | 997.9K | OO | — | 2022-02-11 | ↗ |
| 17 | GP-GP, | 997.9K | 9.70% | — | 997.9K | — | 997.9K | PN | — | 2022-05-09 | ↗ |
| 18 | Versant Venture Capital VI, L.P. | 997.9K | 9.70% | 997.9K | — | 997.9K | — | PN | — | 2022-05-09 | ↗ |
| 19 | Versant Ventures VI GP, L.P. | 997.9K | 9.70% | — | 997.9K | — | 997.9K | PN | — | 2022-05-09 | ↗ |
| 20 | EcoR1 Capital Fund Qualified, L.P. | 984.7K | 11.00% | — | 984.7K | — | — | PN | Delaware | 2023-02-14 | ↗ |
| 21 | Rock Springs Capital LLC | 823.7K | 11.48% | — | 823.7K | — | — | HC, OO | Cayman Islands | 2022-01-03 | ↗ |
| 22 | Rock Springs Capital Management LP | 823.7K | 11.48% | — | 823.7K | — | — | IA | Cayman Islands | 2022-01-03 | ↗ |
| 23 | Rock Springs Capital Master Fund LP | 750.0K | 10.46% | — | 750.0K | — | — | PN | Cayman Islands | 2022-01-03 | ↗ |
| 24 | Roche Finance Ltd | 72.6K | 1.10% | — | — | — | — | CO | Switzerland | 2022-02-14 | ↗ |
| 25 | Roche Holding Ltd | 72.6K | 1.10% | — | — | — | — | CO | Switzerland | 2022-02-14 | ↗ |
| 26 | Chart Westcott | 58.8K | 0.90% | — | 58.8K | — | 58.8K | HC, IN | States | 2022-02-14 | ↗ |
| 27 | Ikarian Capital, LLC | 58.8K | 0.90% | — | 58.8K | — | 58.8K | IA | Delaware | 2022-02-14 | ↗ |
| 28 | Neil Shahrestani | 58.8K | 0.90% | — | 58.8K | — | 58.8K | HC, IN | States | 2022-02-14 | ↗ |
| 29 | Versant Side Fund IV, L.P. | 7.4K | 0.10% | 7.4K | — | 7.4K | — | PN | — | 2022-05-09 | ↗ |
| 30 | 2. | 10.00 | 0.00% | — | 365.00 | — | — | HC, OO | — | 2022-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2025 Q4
Investors holding
20
+2 vs prev Q
New positions
5
Closed positions
2
Increased
8
Reduced
4
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VERSANT VENTURE MANAGEMENT, LLC | 269.8K +— (+0.0%) | 774.2K -2.0M (-72.1%) | 6.08% -1.018 pp | 0.51% -0.793 pp | USD6.80 -57.8% | 5 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 192.8K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 340.20 | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 69.00 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 934.08 | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 159.6K | 0.03% |
| 6 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 349.55 | 0.22% |
| 7 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 190.70 | 0.22% |
| 8 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 76.79 | 0.22% |
| 9 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 8.49 | 0.22% |
| 10 | Vanguard Conservative Income ETF Portfolio VCIP.TO | 0.00% | 1.20 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
8
Sells
0
Shares acquired
668.0K
Shares disposed
—
Cash buys
1.00
Cash sales
—
Net activity
+668,023
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | Trojanowski Justin | Officer | A-Award | A | Employee Stock Option (right to buy) | 22,000 | 1.64 | 36.1K | 22,000 | D | ↗ |
| 2026-03-31 | Maestas Nicholas | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,000 | 1.64 | 229.6K | 140,000 | D | ↗ |
| 2026-03-24 | Angel Matthew | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 231,482 | 2.16 | 500.0K | 231,482 | I | ↗ |
| 2026-02-04 | Angel Matthew | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 269,621 | 2.38 | 641.7K | 269,621 | D | ↗ |
| 2026-02-03 | Angel Matthew | Director / Officer / 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 8,268,495 | I | ↗ |
| 2026-01-27 | Simantov Ronit | Director | A-Award | A | Stock Option (right to buy) | 1,230 | 2.94 | 3.6K | 1,230 | D | ↗ |
| 2026-01-27 | RAAB MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 1,230 | 2.94 | 3.6K | 1,230 | D | ↗ |
| 2026-01-27 | Pellizzari Christine A | Director | A-Award | A | Stock Option (right to buy) | 1,230 | 2.94 | 3.6K | 1,230 | D | ↗ |
| 2026-01-27 | NICHOL GEOFFREY | Director | A-Award | A | Stock Option (right to buy) | 1,230 | 2.94 | 3.6K | 1,230 | D | ↗ |
| 2025-01-02 | Whiting Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 270,000 | 0.86 | 232.2K | 270,000 | D | ↗ |
| 2025-01-02 | Trojanowski Justin | Officer | A-Award | A | Employee Stock Option (right to buy) | 30,000 | 0.86 | 25.8K | 30,000 | D | ↗ |
| 2025-01-02 | Maestas Nicholas | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 0.86 | 172.0K | 200,000 | D | ↗ |
| 2025-01-02 | Brady Stephen R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 550,000 | 0.86 | 473.0K | 550,000 | D | ↗ |
| 2024-08-12 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 387,999 | 1.10 | 427.0K | 209,941 | — | ↗ |
| 2024-08-08 | Versant Venture Capital VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 400,000 | 1.35 | 540.0K | 597,940 | — | ↗ |
| 2024-07-03 | Brady Stephen R | Director / Officer | P-Purchase | A | Common Stock | 35,000 | 2.11 | 73.9K | 46,376 | — | ↗ |
| 2024-07-02 | Whiting Samuel | Officer | P-Purchase | A | Common Stock | 4,672 | 2.13 | 10.0K | 9,573 | — | ↗ |
| 2024-06-28 | Trojanowski Justin | Officer | P-Purchase | A | Common Stock | 7,500 | 2.16 | 16.2K | 22,168 | — | ↗ |
| 2024-06-13 | Simantov Ronit | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.03 | 48.5K | 16,000 | — | ↗ |
| 2024-06-13 | RAAB MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.03 | 48.5K | 16,000 | — | ↗ |
| 2024-06-13 | Pellizzari Christine A | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.03 | 48.5K | 16,000 | — | ↗ |
| 2024-06-13 | NICHOL GEOFFREY | Director | A-Award | A | Stock Option (right to buy) | 16,000 | 3.03 | 48.5K | 16,000 | — | ↗ |
| 2024-01-03 | Whiting Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 4.66 | 466.0K | 100,000 | — | ↗ |
| 2024-01-03 | Trojanowski Justin | Officer | A-Award | A | Employee Stock Option (right to buy) | 26,500 | 4.66 | 123.5K | 26,500 | — | ↗ |
| 2024-01-03 | Maestas Nicholas | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 4.66 | 186.4K | 40,000 | — | ↗ |
| 2024-01-03 | Brady Stephen R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 250,000 | 4.66 | 1.17M | 250,000 | — | ↗ |
| 2023-10-11 | Whiting Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 325,000 | 9.77 | 3.18M | 325,000 | — | ↗ |
| 2023-10-11 | Trojanowski Justin | Officer | A-Award | A | Employee Stock Option (right to buy) | 55,000 | 9.77 | 537.4K | 55,000 | — | ↗ |
| 2023-10-11 | Maestas Nicholas | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 9.77 | 977.0K | 100,000 | — | ↗ |
| 2023-10-11 | Brady Stephen R | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 725,000 | 9.77 | 7.08M | 725,000 | — | ↗ |
| 2023-06-15 | Simantov Ronit | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 1.42 | 11.6K | 8,200 | — | ↗ |
| 2023-06-15 | RAAB MICHAEL | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 1.42 | 11.6K | 8,200 | — | ↗ |
| 2023-06-15 | Pellizzari Christine A | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 1.42 | 11.6K | 8,200 | — | ↗ |
| 2023-06-15 | NICHOL GEOFFREY | Director | A-Award | A | Stock Option (right to buy) | 8,200 | 1.42 | 11.6K | 8,200 | — | ↗ |
| 2023-01-03 | Whiting Samuel | Officer | A-Award | A | Employee Stock Option (right to buy) | 69,700 | 0.00 | — | 69,700 | — | ↗ |
| 2023-01-03 | Trojanowski Justin | Officer | A-Award | A | Employee Stock Option (right to buy) | 20,300 | 0.00 | — | 20,300 | — | ↗ |
| 2023-01-03 | Maestas Nicholas | Officer | A-Award | A | Employee Stock Option (right to buy) | 38,425 | 0.00 | — | 38,425 | — | ↗ |
| 2023-01-03 | Dubensky Thomas W. | Officer | A-Award | A | Employee Stock Option (right to buy) | 102,700 | 0.00 | — | 102,700 | — | ↗ |
| 2023-01-03 | Brady Stephen R | Officer | A-Award | A | Employee Stock Option (right to buy) | 177,300 | 0.00 | — | 177,300 | — | ↗ |
| 2022-10-03 | Trojanowski Justin | Officer | A-Award | A | Employee Stock Option (right to buy) | 2,500 | 0.00 | — | 2,500 | — | ↗ |
| 2022-09-30 | Trojanowski Justin | Officer | — | D | Employee Stock Option (right to buy) | 10,000 | 2.29 | 22.9K | 0 | — | ↗ |
| 2022-06-22 | Whiting Samuel | Officer | A-Award | A | Stock Option (Right to Buy) | 55,680 | 0.00 | — | 55,680 | — | ↗ |
| 2022-06-21 | Maestas Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 51,270 | 0.00 | — | 51,270 | — | ↗ |
| 2022-06-21 | Lorenzo Pierre | Officer | A-Award | A | Stock Option (Right to Buy) | 8,477 | 0.00 | — | 8,477 | — | ↗ |
| 2022-06-21 | Dubensky Thomas W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 87,801 | 2.35 | 206.3K | 87,801 | — | ↗ |
| 2022-06-21 | Brady Stephen R | Officer | A-Award | A | Stock Option (Right to Buy) | 173,533 | 0.00 | — | 173,533 | — | ↗ |
| 2022-06-17 | Woiwode Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 3,500 | 2.08 | 7.3K | 3,500 | — | ↗ |
| 2022-06-17 | Simantov Ronit | Director | A-Award | A | Stock Option (Right to Buy) | 3,500 | 0.00 | — | 3,500 | — | ↗ |
| 2022-06-17 | RAAB MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 3,500 | 0.00 | — | 3,500 | — | ↗ |
| 2022-06-17 | Pellizzari Christine A | Director | A-Award | A | Stock Option (Right to Buy) | 3,500 | 0.00 | — | 3,500 | — | ↗ |
| 2022-06-17 | NICHOL GEOFFREY | Director | A-Award | A | Stock Option (Right to Buy) | 3,500 | 2.08 | 7.3K | 3,500 | — | ↗ |
| 2022-04-29 | Woiwode Thomas | Director | P-Purchase | A | Common Stock | 2,118,644 | 2.36 | 5.00M | 2,118,644 | — | ↗ |
| 2022-04-29 | Versant Venture Capital VI, L.P. | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-04-29 | Versant Vantage II, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,118,644 | — | ↗ |
| 2022-01-07 | Dubensky Thomas W. | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 4.78 | 9.6K | 113,343 | — | ↗ |
| 2022-01-06 | Whiting Samuel | Officer | P-Purchase | A | Common Stock | 1,700 | 4.80 | 8.2K | 1,901 | — | ↗ |
| 2022-01-04 | Whiting Samuel | Officer | A-Award | A | Stock Option (Right to Buy) | 29,000 | 5.45 | 158.1K | 29,000 | — | ↗ |
| 2022-01-04 | Maestas Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 19,500 | 5.45 | 106.3K | 19,500 | — | ↗ |
| 2022-01-04 | Lorenzo Pierre | Officer | A-Award | A | Stock Option (Right to Buy) | 6,500 | 5.45 | 35.4K | 6,500 | — | ↗ |
| 2022-01-04 | Dubensky Thomas W. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 53,100 | 5.45 | 289.4K | 53,100 | — | ↗ |
| 2022-01-04 | Brady Stephen R | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 94,500 | 5.45 | 515.0K | 94,500 | — | ↗ |
| 2021-12-30 | Rock Springs Capital Management LP | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 750,000 | — | ↗ |
| 2021-09-21 | RAAB MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 6,635 | 15.15 | 100.5K | 6,635 | — | ↗ |
| 2021-08-06 | Simantov Ronit | Director | A-Award | A | Stock Option (Right to Buy) | 6,635 | 13.60 | 90.2K | 6,635 | — | ↗ |
| 2021-07-12 | Maestas Nicholas | Officer | A-Award | A | Stock Option (Right to Buy) | 23,225 | 24.19 | 561.8K | 23,225 | — | ↗ |
| 2021-07-01 | Xu Stella | — | A-Award | A | Stock Option (Right to Buy) | 6,635 | 11.07 | 73.4K | 6,635 | — | ↗ |
| 2021-07-01 | Woiwode Thomas | Director | A-Award | A | Stock Option (Right to Buy) | 6,635 | 11.07 | 73.4K | 6,635 | — | ↗ |
| 2021-07-01 | Pellizzari Christine A | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-07-01 | NICHOL GEOFFREY | — | A-Award | A | Stock Option (Right to Buy) | 6,635 | 11.07 | 73.4K | 6,635 | — | ↗ |
| 2021-06-25 | Xu Stella | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-25 | Woiwode Thomas | — | A-Award | A | Common Stock | 1,171,094 | 1.06 | 1.24M | 1,171,094 | — | ↗ |
| 2021-06-25 | Whiting Samuel | — | A-Award | A | Stock Option (Right to Buy) | 540,231 | 26.40 | 14.26M | 540,231 | — | ↗ |
| 2021-06-25 | Versant Venture Capital VI, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 997,940 | — | ↗ |
| 2021-06-25 | RAAB MICHAEL | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-25 | Lorenzo Pierre | — | A-Award | A | Stock Option (Right to Buy) | 1,234 | 10.25 | 12.6K | 1,234 | — | ↗ |
| 2021-06-25 | Dubensky Thomas W. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-25 | Brady Stephen R | — | A-Award | A | Stock Option (Right to Buy) | 70,256 | 5.90 | 414.5K | 70,256 | — | ↗ |
| 2021-03-17 | Owens Julia C. | Director / Officer | A-Award | A | Stock Option (right to buy) | 24,000 | 2.29 | 55.0K | 24,000 | — | ↗ |
| 2021-02-26 | Minai-Azary Jennifer Lynn | Officer | A-Award | A | Stock Option (right to buy) | 110,000 | 2.06 | 226.6K | 110,000 | — | ↗ |
| 2021-02-26 | Arcudi III Louis J | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 2.06 | 824.0K | 400,000 | — | ↗ |
| 2021-02-01 | Minai-Azary Jennifer Lynn | Officer | — | D | Stock Option (right to buy) | 989 | 2.69 | 2.7K | 0 | — | ↗ |
| 2020-06-22 | Nuechterlein Carole | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-06-22 | NICHOL GEOFFREY | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-06-22 | Hindman James M. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-06-22 | Hedley Mary Lynne | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-06-22 | HOWE JOHN P MD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-06-22 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-06-22 | Dable Habib J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 2.40 | 28.8K | 12,000 | — | ↗ |
| 2020-05-25 | Zeidan Ryan | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.00 | 160.0K | 80,000 | — | ↗ |
| 2020-05-25 | Owens Julia C. | Director / Officer | A-Award | A | Stock Option (right to buy) | 282,000 | 2.00 | 564.0K | 282,000 | — | ↗ |
| 2020-05-25 | JOSEPH TAMARA L | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.00 | 160.0K | 80,000 | — | ↗ |
| 2020-05-25 | Arcudi III Louis J | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.00 | 160.0K | 80,000 | — | ↗ |
| 2020-05-25 | Arbet-Engels Christophe | Officer | A-Award | A | Stock Option (right to buy) | 80,000 | 2.00 | 160.0K | 80,000 | — | ↗ |
| 2020-03-28 | Zeidan Ryan | Officer | A-Award | A | Employee Stock Option (right to buy) | 15,000 | 4.80 | 72.0K | 15,000 | — | ↗ |
| 2020-02-10 | Arbet-Engels Christophe | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,000 | 6.90 | 966.0K | 140,000 | — | ↗ |
| 2020-01-31 | Zeidan Ryan | Officer | A-Award | A | Employee Stock Option (right to buy) | 41,250 | 7.94 | 327.5K | 41,250 | — | ↗ |
| 2020-01-31 | Owens Julia C. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 215,000 | 7.94 | 1.71M | 215,000 | — | ↗ |
| 2020-01-31 | JOSEPH TAMARA L | Officer | A-Award | A | Employee Stock Option (right to buy) | 56,250 | 7.94 | 446.6K | 56,250 | — | ↗ |
| 2020-01-31 | Arcudi III Louis J | Officer | A-Award | A | Employee Stock Option (right to buy) | 71,250 | 7.94 | 565.7K | 71,250 | — | ↗ |
| 2019-12-17 | NICHOL GEOFFREY | Director | A-Award | A | Stock Option (right to buy) | 24,000 | 6.29 | 151.0K | 24,000 | — | ↗ |
| 2019-08-19 | Zeidan Ryan | Officer | A-Award | A | Employee Stock Option (right to buy) | 10,000 | 7.27 | 72.7K | 10,000 | — | ↗ |
| 2019-08-19 | JOSEPH TAMARA L | Officer | A-Award | A | Employee Stock Option (right to buy) | 130,000 | 7.27 | 945.1K | 130,000 | — | ↗ |
| 2019-08-16 | Zeidan Ryan | Officer | — | D | Employee Stock Option (right to buy) | 5,000 | 11.59 | 58.0K | 0 | — | ↗ |
| 2019-06-20 | WHITCOMB RANDALL W | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | Owens Julia C. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 76,007 | 11.59 | 880.9K | 76,007 | — | ↗ |
| 2019-06-20 | Nuechterlein Carole | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | Hindman James M. | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | Hedley Mary Lynne | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | HOWE JOHN P MD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | Dable Habib J | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 11.59 | 139.1K | 12,000 | — | ↗ |
| 2019-06-20 | Arcudi III Louis J | Officer | A-Award | A | Employee Stock Option (right to buy) | 25,000 | 11.59 | 289.8K | 25,000 | — | ↗ |
| 2019-01-15 | WHITCOMB RANDALL W | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | Owens Julia C. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 173,993 | 8.80 | 1.53M | 173,993 | — | ↗ |
| 2019-01-15 | Nuechterlein Carole | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | Mohideen Pharis | Officer | A-Award | A | Employee Stock Option (right to buy) | 64,000 | 8.80 | 563.2K | 64,000 | — | ↗ |
| 2019-01-15 | Hindman James M. | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | Hedley Mary Lynne | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | HOWE JOHN P MD | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | Gallagher Carol Giltner | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | Dable Habib J | Director | A-Award | A | Stock Option (right to buy) | 6,000 | 8.80 | 52.8K | 6,000 | — | ↗ |
| 2019-01-15 | Brinza Jeffery M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 56,000 | 8.80 | 492.8K | 56,000 | — | ↗ |
| 2019-01-15 | Arcudi III Louis J | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 8.80 | 440.0K | 50,000 | — | ↗ |
| 2018-12-07 | WHITCOMB RANDALL W | Director | A-Award | A | Common Stock | 15,784 | 0.00 | — | 15,784 | — | ↗ |
| 2018-12-07 | Sonsini Peter W. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | SANDELL SCOTT D | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | Owens Julia C. | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | Nuechterlein Carole | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | New Enterprise Associates 15, L.P. | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | Mohideen Pharis | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | Makhzoumi Mohamad | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | MOTT DAVID M | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | MAKOWER JOSHUA | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | KOZIN MARC D | Director | A-Award | A | Common Stock | 831 | 0.00 | — | 7,740 | — | ↗ |
| 2018-12-07 | Hindman James M. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | Hedley Mary Lynne | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | Gallagher Carol Giltner | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | Florence Anthony A. Jr. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | FISHER MARY | Director | A-Award | A | Common Stock | 355 | 0.00 | — | 3,319 | — | ↗ |
| 2018-12-07 | FHM VI, L.L.C. | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,396,615 | — | ↗ |
| 2018-12-07 | Dable Habib J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-12-07 | Brinza Jeffery M. | Officer | A-Award | A | Employee Stock Option (right to buy) | 44,639 | 16.40 | 732.1K | 44,639 | — | ↗ |
| 2018-12-07 | BASKETT FOREST | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | BARRIS PETER J | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 1,766,407 | — | ↗ |
| 2018-12-07 | Arcudi III Louis J | Officer | A-Award | A | Employee Stock Option (right to buy) | 74,400 | 10.40 | 773.4K | 74,400 | — | ↗ |
| 2018-12-07 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 755 | 0.00 | — | 6,169 | — | ↗ |
| 2018-09-28 | KOZIN MARC D | Director | A-Award | A | Common Stock | 16,014 | 0.00 | — | 103,647 | — | ↗ |
| 2018-09-28 | FISHER MARY | Director | A-Award | A | Common Stock | 6,851 | 0.00 | — | 44,460 | — | ↗ |
| 2018-09-28 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 14,558 | 0.00 | — | 81,220 | — | ↗ |
| 2018-07-04 | Sexton John | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.95 | 11.5K | 12,000 | — | ↗ |
| 2018-07-04 | KOZIN MARC D | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.95 | 11.5K | 12,000 | — | ↗ |
| 2018-07-04 | HOWE JOHN P MD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.95 | 11.5K | 12,000 | — | ↗ |
| 2018-07-04 | FISHER MARY | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.95 | 11.5K | 12,000 | — | ↗ |
| 2018-07-04 | CAPELLO JEFFREY D | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.95 | 11.5K | 12,000 | — | ↗ |
| 2018-07-04 | ALDRICH RICHARD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 0.95 | 11.5K | 12,000 | — | ↗ |
| 2018-06-29 | KOZIN MARC D | Director | A-Award | A | Common Stock | 12,880 | 0.00 | — | 87,633 | — | ↗ |
| 2018-06-29 | FISHER MARY | Director | A-Award | A | Common Stock | 5,510 | 0.00 | — | 37,609 | — | ↗ |
| 2018-06-29 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 11,709 | 0.00 | — | 66,662 | — | ↗ |
| 2018-05-10 | Lillie James Woodruff | Officer | A-Award | A | Employee Stock Option (right to buy) | 8,333 | 13.98 | 116.5K | 8,333 | — | ↗ |
| 2018-05-10 | Kroeger Christopher A. | Officer | A-Award | A | Employee Stock Option (right to buy) | 47,666 | 13.98 | 666.4K | 47,666 | — | ↗ |
| 2018-05-10 | GILLIS JONATHAN | Officer | A-Award | A | Employee Stock Option (right to buy) | 5,000 | 13.98 | 69.9K | 5,000 | — | ↗ |
| 2018-03-30 | KOZIN MARC D | Director | A-Award | A | Common Stock | 14,411 | 0.00 | — | 74,753 | — | ↗ |
| 2018-03-30 | FISHER MARY | Director | A-Award | A | Common Stock | 6,165 | 0.00 | — | 32,099 | — | ↗ |
| 2018-03-30 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 13,101 | 0.00 | — | 54,953 | — | ↗ |
| 2018-03-06 | Lillie James Woodruff | Officer | A-Award | A | Stock Option (right to buy) | 357,057 | 1.02 | 364.2K | 357,057 | — | ↗ |
| 2018-02-08 | GILLIS JONATHAN | Officer | A-Award | A | Stock Option (right to buy) | 128,645 | 0.93 | 119.6K | 128,645 | — | ↗ |
| 2018-01-16 | Lillie James Woodruff | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-12-29 | KOZIN MARC D | Director | A-Award | A | Common Stock | 8,348 | 0.00 | — | 60,342 | — | ↗ |
| 2017-12-29 | FISHER MARY | Director | A-Award | A | Common Stock | 3,571 | 0.00 | — | 25,934 | — | ↗ |
| 2017-12-29 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 7,589 | 0.00 | — | 41,852 | — | ↗ |
| 2017-09-29 | KOZIN MARC D | Director | A-Award | A | Common Stock | 8,230 | 0.00 | — | 51,994 | — | ↗ |
| 2017-09-29 | FISHER MARY | Director | A-Award | A | Common Stock | 3,521 | 0.00 | — | 22,363 | — | ↗ |
| 2017-09-29 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 7,482 | 0.00 | — | 34,263 | — | ↗ |
| 2017-09-01 | Kroeger Christopher A. | Director / Officer | — | D | Stock Option (right to buy) | 1,783,106 | 1.46 | 2.60M | 0 | — | ↗ |
| 2017-06-30 | KOZIN MARC D | Director | A-Award | A | Common Stock | 6,477 | 0.00 | — | 43,764 | — | ↗ |
| 2017-06-30 | FISHER MARY | Director | A-Award | A | Common Stock | 3,205 | 0.00 | — | 18,842 | — | ↗ |
| 2017-06-30 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 6,810 | 0.00 | — | 26,781 | — | ↗ |
| 2017-06-21 | Sexton John | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.46 | 17.5K | 12,000 | — | ↗ |
| 2017-06-21 | KOZIN MARC D | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.46 | 17.5K | 12,000 | — | ↗ |
| 2017-06-21 | HOWE JOHN P MD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.46 | 17.5K | 12,000 | — | ↗ |
| 2017-06-21 | GILLIS JONATHAN | Officer | — | D | Stock Option (right to buy) | 7,500 | 42.10 | 315.8K | 0 | — | ↗ |
| 2017-06-21 | FISHER MARY | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.46 | 17.5K | 12,000 | — | ↗ |
| 2017-06-21 | Dipp Michelle | Director / Officer | A-Award | A | Stock Option (right to buy) | 175,000 | 1.46 | 255.5K | 175,000 | — | ↗ |
| 2017-06-21 | CAPELLO JEFFREY D | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.46 | 17.5K | 12,000 | — | ↗ |
| 2017-06-21 | ALDRICH RICHARD | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 1.46 | 17.5K | 12,000 | — | ↗ |
| 2017-06-13 | Malley Thomas | Director | A-Award | A | Common Stock | 7,873 | 0.00 | — | 204,981 | — | ↗ |
| 2017-03-31 | Malley Thomas | Director | A-Award | A | Common Stock | 7,085 | 0.00 | — | 197,108 | — | ↗ |
| 2017-03-31 | KOZIN MARC D | Director | A-Award | A | Common Stock | 5,180 | 0.00 | — | 37,287 | — | ↗ |
| 2017-03-31 | FISHER MARY | Director | A-Award | A | Common Stock | 2,673 | 0.00 | — | 15,637 | — | ↗ |
| 2017-03-31 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 5,681 | 0.00 | — | 19,971 | — | ↗ |
| 2017-03-02 | Dipp Michelle | Director / Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 1.49 | 223.5K | 150,000 | — | ↗ |
| 2017-03-02 | Couturier Christophe | Officer | A-Award | A | Stock Option (right to buy) | 45,750 | 1.49 | 68.2K | 45,750 | — | ↗ |
| 2017-01-05 | Couturier Christophe | Officer | A-Award | A | Stock Option (right to buy) | 100,000 | 1.64 | 164.0K | 100,000 | — | ↗ |
| 2016-12-30 | Malley Thomas | Director | A-Award | A | Common Stock | 8,660 | 1.53 | 13.2K | 190,023 | — | ↗ |
| 2016-12-30 | KOZIN MARC D | Director | A-Award | A | Common Stock | 6,331 | 1.53 | 9.7K | 32,107 | — | ↗ |
| 2016-12-30 | FISHER MARY | Director | A-Award | A | Common Stock | 3,267 | 1.53 | 5.0K | 12,964 | — | ↗ |
| 2016-12-30 | ALDRICH RICHARD | Director | A-Award | A | Common Stock | 6,944 | 1.53 | 10.6K | 14,290 | — | ↗ |
| 2016-12-23 | Couturier Christophe | Officer | A-Award | A | Common Stock | 300 | 1.44 | 431.16 | 50,900 | — | ↗ |
| 2016-12-22 | ALDRICH RICHARD | Director | G-Gift | A | Common Stock | 154,519 | 0.00 | — | 330,000 | — | ↗ |
| 2016-12-13 | ALDRICH RICHARD | Director | G-Gift | D | Common Stock | 645,842 | 0.00 | — | 161,865 | — | ↗ |
Executive team
Top executives
Shares Outstanding
4.44M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Stephen Brady Chief Executive Officer and President | 600.0K | — | — | 978.0K | 280.5K | 13.8K | 1.87M | 52.24% | ↗ |
| 2 | 2024 | Samuel Whiting Chief Medical Officer | 481.7K | — | — | 391.2K | 175.8K | 13.8K | 1.06M | 36.82% | ↗ |
| 3 | 2024 | Nicholas Maestas Chief Financial Officer | 365.5K | — | — | 156.5K | 100.1K | — | 622.1K | 25.15% | ↗ |
| 4 | 2023 | Stephen Brady Chief Executive Officer and President | 567.0K | — | — | 6.08M | 343.0K | 13.2K | 7.01M | 86.82% | ↗ |
| 5 | 2023 | Stephen Brady Chief Executive Officer and President | 567.0K | — | — | 6.08M | 343.0K | 13.2K | 7.01M | 86.82% | ↗ |
| 6 | 2023 | Samuel Whiting Chief Medical Officer | 454.5K | — | — | 2.72M | 200.0K | 13.2K | 3.38M | 80.28% | ↗ |
| 7 | 2023 | Samuel Whiting Chief Medical Officer | 454.5K | — | — | 2.72M | 200.0K | 13.2K | 3.38M | 80.28% | ↗ |
| 8 | 2023 | Nicholas Maestas Chief Financial Officer | 351.5K | — | — | 853.6K | 113.4K | 586.00 | 1.32M | 64.71% | ↗ |
| 9 | 2022 | Stephen Brady Chief Executive Officer | 530.0K | — | — | 773.4K | 198.8K | 12.2K | 1.51M | 51.07% | ↗ |
| 10 | 2022 | Stephen Brady Chief Executive Officer and President | 530.0K | — | — | 773.4K | 198.8K | 12.2K | 1.51M | 51.07% | ↗ |
| 11 | 2022 | Thomas Dubensky President | 489.5K | — | — | 415.3K | 183.6K | 12.2K | 1.10M | 37.73% | ↗ |
| 12 | 2022 | Samuel Whiting Chief Medical Officer | 437.0K | — | — | 242.2K | 142.0K | 12.2K | 833.4K | 29.06% | ↗ |
| 13 | 2021 | Louis Arcudi III Former Chief Executive Officer | 211.7K | 880.0K | — | 541.3K | — | — | 1.63M | 33.15% | ↗ |
| 14 | 2021 | Thomas Dubensky President | 475.3K | — | — | 562.1K | 190.1K | 272.7K | 1.50M | 37.47% | ↗ |
| 15 | 2021 | Thomas Dubensky President | 475.3K | — | — | 562.1K | 190.1K | 272.7K | 1.50M | 37.47% | ↗ |
| 16 | 2021 | Julia C. Owens Former Chief Executive Officer | 120.4K | — | — | 35.2K | — | 1.18M | 1.34M | 2.63% | ↗ |
| 17 | 2021 | Samuel Whiting Chief Medical Officer | 400.0K | — | — | 296.7K | 140.0K | — | 836.7K | 35.46% | ↗ |
| 18 | 2021 | Samuel Whiting Chief Medical Officer | 400.0K | — | — | 296.7K | 140.0K | — | 836.7K | 35.46% | ↗ |
| 19 | 2021 | Stephen Brady Chief Executive Officer | 475.3K | — | — | 49.3K | 190.1K | — | 714.7K | 6.90% | ↗ |
| 20 | 2021 | Stephen Brady Chief Executive Officer | 475.3K | — | — | 49.3K | 190.1K | — | 714.7K | 6.90% | ↗ |
| 21 | 2020 | Julia C. Owens Former Chief Executive Officer | 526.3K | — | — | 1.48M | 263.2K | 8.6K | 2.28M | 65.03% | ↗ |
| 22 | 2020 | Louis Arcudi III Former Chief Executive Officer | 378.4K | — | — | 437.9K | 151.4K | 8.6K | 976.2K | 44.86% | ↗ |
| 23 | 2019 | Julia C. Owens Chief Executive Officer | 478.9K | — | — | 1.68M | 215.5K | 8.4K | 2.38M | 70.49% | ↗ |
| 24 | 2019 | Louis Arcudi Former Chief Executive Officer | 350.0K | — | — | 507.6K | 126.0K | 19.8K | 1.00M | 50.59% | ↗ |
| 25 | 2019 | Ryan Zeidan | 320.6K | 40.0K | — | 337.5K | 106.6K | 44.5K | 849.1K | 39.74% | ↗ |
| 26 | 2018 | Julia C. Owens Chief Executive Officer | 432.6K | 50.0K | — | 1.75M | 179.5K | 8.3K | 2.42M | 72.35% | ↗ |
| 27 | 2018 | Christopher Kroeger, M.D., M.B.A Former Chief Executive Officer | 513.8K | 330.0K | — | 403.7K | — | 810.6K | 2.06M | 19.62% | ↗ |
| 28 | 2018 | Pharis Mohideen Chief Medical Officer | 367.6K | — | — | 410.5K | 106.8K | 35.0K | 919.9K | 44.62% | ↗ |
| 29 | 2018 | Jeffery M. Brinza | 308.1K | 16.0K | — | 447.8K | 89.5K | 8.3K | 869.7K | 51.49% | ↗ |
| 30 | 2018 | Jonathan Gillis, C.P.A. Former Senior Vice President, Finance | 252.2K | 94.5K | — | 104.3K | — | 203.8K | 654.8K | 15.92% | ↗ |
| 31 | 2017 | Christopher Kroeger, M.D., M.B.A Former Chief Executive Officer | 292.1K | 131.5K | — | 1.99M | — | 16.4K | 2.43M | 81.89% | ↗ |
| 32 | 2017 | Christopher Kroeger, M.D., M.B.A. | 292.1K | 131.5K | — | 1.99M | — | 16.4K | 2.43M | 81.89% | ↗ |
| 33 | 2017 | Michelle Dipp, M.D., Ph.D. Former Chief Executive Officer and Executive Chair | 334.2K | 75.0K | — | 359.4K | — | 248.7K | 1.02M | 35.33% | ↗ |
| 34 | 2017 | Julia C. Owens Chief Executive Officer | 420.0K | 83.2K | — | — | 84.8K | 8.1K | 596.1K | 0.00% | ↗ |
| 35 | 2017 | Christophe Couturier Former Chief Financial Officer | 243.9K | 155.0K | — | 175.1K | — | 11.2K | 585.2K | 29.92% | ↗ |
| 36 | 2017 | Pharis Mohideen Chief Medical Officer | 356.9K | 49.5K | — | — | 50.5K | 25.1K | 481.9K | 0.00% | ↗ |
| 37 | 2017 | Jonathan Gillis, C.P.A. Former Senior Vice President, Finance | 229.0K | 187.5K | — | 51.5K | — | 9.0K | 477.0K | 10.80% | ↗ |
| 38 | 2017 | Jonathan Gillis, C.P.A. Former Senior Vice President, Finance | 229.0K | 187.5K | — | 51.5K | — | 9.0K | 477.0K | 10.80% | ↗ |
| 39 | 2016 | Harald Stock, Ph.D.. | 627.4K | 200.0K | 2.36M | 1.61M | — | 952.4K | 5.75M | 69.03% | ↗ |
| 40 | 2016 | Paul Chapman | 351.4K | 75.0K | — | 1.71M | — | 320.9K | 2.46M | 69.62% | ↗ |
| 41 | 2016 | Christophe Couturier Former Chief Financial Officer | 113.8K | 139.2K | 357.5K | 1.04M | — | 7.0K | 1.65M | 84.26% | ↗ |
| 42 | 2016 | Christophe Couturier Former Chief Financial Officer | 113.8K | 139.2K | 357.5K | 1.04M | — | 7.0K | 1.65M | 84.26% | ↗ |
| 43 | 2016 | Michelle Dipp, M.D., Ph.D. Former Chief Executive Officer and Executive Chair | 478.8K | 333.0K | — | — | — | 18.6K | 860.4K | 0.00% | ↗ |
| 44 | 2016 | Michelle Dipp, M.D., Ph.D. Executive Chair | 478.8K | 333.0K | — | — | — | 18.6K | 830.4K | 0.00% | ↗ |
| 45 | 2016 | Jeffrey E. Young Former Chief Financial Officer | 299.6K | — | — | — | — | 378.1K | 677.7K | 0.00% | ↗ |
| 46 | 2016 | Arthur Tzianabos, Ph.D. Former President and Chief Scientific Officer | 121.0K | — | — | — | — | 328.9K | 449.9K | 0.00% | ↗ |
| 47 | 2015 | Jeffrey E. Young Former Chief Financial Officer | 308.5K | 114.0K | 367.9K | — | — | 8.0K | 798.3K | 46.08% | ↗ |
| 48 | 2015 | Jeffrey E. Young Former Chief Financial Officer | 308.5K | 114.0K | 367.9K | — | — | 8.0K | 798.3K | 46.08% | ↗ |
| 49 | 2015 | Arthur Tzianabos, Ph.D. Former President and Chief Scientific Officer | 422.7K | 127.5K | 183.9K | — | — | 13.5K | 747.6K | 24.60% | ↗ |
| 50 | 2015 | Michelle Dipp, M.D., Ph.D. Executive Chair | — | — | 435.8K | — | — | — | 435.8K | 100.00% | ↗ |
| 51 | 2015 | Michelle Dipp, M.D., Ph.D. Executive Chair and Chief Executive Officer | — | — | 435.8K | — | — | — | 435.8K | 100.00% | ↗ |
| 52 | 2015 | Michelle Dipp, M.D., Ph.D. Former Chief Executive Officer and Executive Chair | — | — | 435.8K | — | — | — | 435.8K | 100.00% | ↗ |
| 53 | 2015 | David Harding Former Chief Commercial | 242.3K | 80.0K | — | — | — | 89.6K | 411.9K | 0.00% | ↗ |
| 54 | 2015 | Theresa McNeely | 283.1K | — | — | — | — | 31.0K | 314.0K | 0.00% | ↗ |
| 55 | 2014 | Michelle Dipp, M.D., Ph.D. Executive Chair | — | — | 1.28M | — | — | — | 5.63M | 22.75% | ↗ |
| 56 | 2014 | Michelle Dipp, M.D., Ph.D. Executive Chair and Chief Executive Officer | — | — | 1.28M | 4.35M | — | — | 5.63M | 100.00% | ↗ |
| 57 | 2014 | Michelle Dipp, M.D., Ph.D. Chief Executive Officer | — | — | 1.28M | 4.35M | — | — | 5.63M | 100.00% | ↗ |
| 58 | 2014 | David Harding Former Chief Commercial | 12.7K | 8.4K | — | 4.46M | — | 761.00 | 4.48M | 99.51% | ↗ |
| 59 | 2014 | David Harding Former Chief Commercial | 12.7K | 8.4K | — | 4.46M | — | 761.00 | 4.48M | 99.51% | ↗ |
| 60 | 2014 | Arthur Tzianabos, Ph.D. President and Chief Scientific | 350.0K | 294.0K | — | 3.51M | — | 13.3K | 4.16M | 84.22% | ↗ |
| 61 | 2014 | Arthur Tzianabos, Ph.D. Former President and Chief Scientific Officer | 350.0K | 294.0K | — | 3.51M | — | 13.3K | 4.16M | 84.22% | ↗ |
| 62 | 2013 | Alison Lawton Former Chief Operating Officer | 323.1K | — | — | 4.67M | — | 10.2K | 5.00M | 93.34% | ↗ |
| 63 | 2013 | Arthur Tzianabos, Ph.D. President and Chief Scientific | 106.3K | — | — | 4.25M | — | 504.00 | 4.35M | 97.55% | ↗ |
| 64 | 2013 | Arthur Tzianabos, Ph.D. Chief Scientific Officer | 106.3K | — | — | 4.25M | — | 504.00 | 4.35M | 97.55% | ↗ |
| 65 | 2013 | Arthur Tzianabos, Ph.D. Former President and Chief Scientific Officer | 106.3K | — | — | 4.25M | — | 504.00 | 4.35M | 97.55% | ↗ |
| 66 | 2013 | Michelle Dipp, M.D., Ph.D. Executive Chair and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 67 | 2013 | Michelle Dipp, M.D., Ph.D. Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 68 | 2012 | Michelle Dipp, M.D., Ph.D. Chief Executive Officer | — | — | 1.50M | 1.94M | — | — | 3.44M | 100.00% | ↗ |
| 69 | 2012 | Christopher Bleck Chief Commercial Officer | 240.0K | 70.0K | — | 298.3K | — | 10.9K | 619.2K | 48.18% | ↗ |
| 70 | 2012 | Scott Chappel, Ph.D. Chief Scientific Officer | 300.0K | 108.0K | — | — | — | 16.2K | 424.2K | 0.00% | ↗ |
| 71 | 2012 | Alison Lawton Former Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 72 | 2012 | Arthur Tzianabos, Ph.D. Chief Scientific Officer | — | — | — | — | — | — | — | — | ↗ |
| 73 | 2011 | Scott Chappel, Ph.D. Chief Scientific Officer | 136.2K | 129.5K | — | 215.0K | — | 248.00 | 480.9K | 44.71% | ↗ |
| 74 | 2011 | Christopher Bleck Chief Commercial Officer | 27.7K | — | — | 256.0K | — | — | 283.6K | 90.24% | ↗ |
| 75 | 2011 | Michelle Dipp, M.D., Ph.D. Chief Executive Officer | — | — | 1.4K | — | — | — | 1.4K | 100.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nicholas Maestas | Chief Financial Officer, Head of Corporate Strategy & Secretary | 914.2K | male |
| Matthew Angel | Chief Executive Officer, President & Director | 894.3K | — |
| Andrew Fang | Head of Business Development | — | — |
| Justin Trojanowski | Corporate Controller, Treasurer & Principal Accounting Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for TPST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
